发明名称 Diazonamide analogs
摘要 Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.
申请公布号 US8846734(B2) 申请公布日期 2014.09.30
申请号 US201314089655 申请日期 2013.11.25
申请人 Joyant Pharmaceuticals, Inc. 发明人 Wei Qi;Zhou Ming;Xu Xiaoming;Caldwell Charles;Harran Susan;Wang Lai
分类号 A01N43/76;A61K31/42;A61P35/00;C07D498/08;C07D498/22;C07D491/04;C07D498/06;C07F9/6561;C07D498/20;C07D519/00 主分类号 A01N43/76
代理机构 代理人 Osman Richard Aron
主权项 1. A compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein: R1 is isopropyl or t-butyl; R2, R4 and R6 are independently H or methyl; R3 is —CRaRbRc wherein Ra is OH, OR, CH2OR, SR, and NR2, where each R is independently H, optionally halogenated C1-C4 alkyl, or optionally fluorinated C1-C4 acyl; and each of Rb and Rc is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylalkyl, C6-C12 aryl, C7-C14 arylalkyl, or a heteroform of one of these, each of which may be optionally substituted; or Rb and Rc may be taken together with the carbon to which they are attached to form a C3-C8 cycloalkyl or hetero-form thereof, which may be optionally substituted; R5 is an optionally substituted oxazole or thiazole ring; R6 is H, or optionally substituted C1-C4 alkyl; Y is at one or more of positions 4, 5, 6 and 7, and Y′ is at one or more of positions 2,3 and 6, wherein the positions are as indicated in formula II: wherein R6 is as defined in formula (I), and Y and Y′ is each independently halo, OH, C1-C4 alkoxy, or C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C12 aryl, or C7-C14 arylalkyl, or a heteroform of one of these, each of which may be optionally substituted; m is 3, 2, 1 or 0; and m′ is 2, 1 or 0, wherein optionally substituted means, for alkyl, alkenyl and alkynyl groups: halo, OH, ═O, ═N—CN, ═N—OR, ═NR, OR, NR2, SR, SOR, SO2R, SO2NR2, NRSO2R, NRCONR2, NRCOOR, NRCOR, CN, COOR, CONR2, OOCR, COR, and NO2, wherein each R is independently H, optionally fluorinated C1-C8 alkyl, C1-C8 acyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C12 aryl, C5-C20 arylalkyl, or a heteroform of these and each R is optionally substituted with one or more groups selected from halo, OH, ═O, ═N—CN, ═N—OR′, ═NR′, OR′, NR′2, SR′, SOR′, SO2R′, SO2NR′2, NR′SO2R′, NR′CONR′2, NR′COOR′, NR′COR′, CN, COOR′, CONR′2, 00CR′, COR′, and NO2, wherein each R′ is independently H, optionally fluorinated C1-C8 alkyl, C1-C8 acyl, C6-C12 aryl , C5-C20 arylalkyl, or a heteroform of these; and for aryl, heteroaryl and heterocyclyl groups: optionally fluorinated C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 acyl, and heteroforms of these, C6-C12 aryl, C6-20 arylalkyl, and heteroforms of these, each optionally substituted, or halo, OH, OR, CH2OH, CH2OR, CH2NR2, NR2, SR, SOR, SO2R, SO2NR2, NRSO2R, NRCONR2, NRCOOR, NRCOR, CN, COOR, CONR2, OOCR, C(O)R, and NO2, wherein each R is independently H, optionally fluorinated C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C12 aryl, C7-C20 arylalkyl, and heteroforms of these, and each R is optionally substituted, and wherein the prefix “hetero” means comprising 1-2 heteroatoms that are independently O, S or N.
地址 Dallas TX US